LOS ANGELES, June 24, 2004 (PRIMEZONE) -- Bio-Life labs, Inc. (OTCBB:BLFE) announced today that it has consolidated its laboratory, research, and development operations into a 32,000 square-foot facility in the El Paso, Texas area.
"This move reflects the strategic growth we expect to achieve in the future and is an important step toward commercializing our skin cancer treatment product candidate Carcinoderm(tm)", said Nancy LeMay, President and Chief Executive Officer of Bio-Life Labs, Inc. "The new office space and research laboratories will support our continued growth as we advance Carcinoderm(tm) through ongoing clinical trials and eventually through the FDA process, and continue pre-clinical programs to expand the application and delivery methods for Carcinoderm(tm) in order to target various solid tumor cancers, as well as to investigate treatments for Diabetes Mellitus and Hepatitis C."
The new facility houses Bio-Life Labs' laboratory, clinical development, regulatory, analytical, and research divisions, and has the capacity to accommodate biologics manufacturing to produce Carcinoderm(tm) for use in the company's ongoing clinical trials, and production capacity for commercial sales when product approval is obtained from the Food and Drug Administration and other regulatory authorities.
Bio-Life Labs, Inc. will continue to maintain its corporate offices in Los Angeles, California.
About Bio-Life Labs, Inc.
Bio-Life, Labs, Inc. is a research-driven biotechnology company focused on discovery, development, and commercialization of breakthrough treatments for Cancer, Diabetes Mellitus, Hepatitis C, and other serious illnesses. The Company's lead product candidate Carcinoderm(tm) is a topical ointment that we have formulated to destroy skin cancer cells in patients diagnosed with Basal Cell Carcinoma, Squamous Cell Carcinoma, and Melanoma, using a single application that does not harm surrounding healthy tissue.
Bio-Life labs, Inc. cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Bio-Life labs, Inc. that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Bio-Life labs, Inc.'s business including, without limitation, statements about: difficulties or delays in research, development, testing, obtaining regulatory approval, producing and marketing its technologies and products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; its ability to meet product development objectives; competition from other pharmaceutical or biotechnology companies; its ability to obtain additional financing to support its operations; its ability to attract and retain experienced scientists and management; as well as other risks detailed in Bio-Life labs, Inc.'s Securities and Exchange Commission filings. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Bio-Life labs, Inc. undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.